Mostrar el registro sencillo del ítem

dc.contributor.authorMartinez-Lopez, J
dc.contributor.authorSanchez-Vega, B
dc.contributor.authorBarrio, S
dc.contributor.authorCuenca, I
dc.contributor.authorRuiz-Heredia, Y
dc.contributor.authorAlonso, R
dc.contributor.authorRapado, I
dc.contributor.authorMarin, C
dc.contributor.authorCedena, M-T
dc.contributor.authorPaiva, B
dc.contributor.authorPuig, N
dc.contributor.authorMateos, M-V
dc.contributor.authorAyala, R
dc.contributor.authorHernandez, M-T
dc.contributor.authorJimenez, C
dc.contributor.authorRosinol, L
dc.contributor.authorMartinez, R
dc.contributor.authorTeruel, Ana Isabel
dc.contributor.authorGutierrez, N
dc.contributor.authorMartin-Ramos, Maria-Luisa
dc.contributor.authorOriol, A
dc.contributor.authorBargay Lleonart, Joan
dc.contributor.authorBlade, J
dc.contributor.authorSan-Miguel, J
dc.contributor.authorGarcia-Sanz, R
dc.contributor.authorLahuerta, J-J
dc.date.accessioned2024-07-11T09:07:19Z
dc.date.available2024-07-11T09:07:19Z
dc.date.issued2017-06
dc.identifier.citationMartinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, et al. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma [letter]. Leukemia. 2017 Jun;31(6):1446-9. Epub 2017 Feb 17.en
dc.identifier.issn0887-6924
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/10944
dc.identifier.urihttp://hdl.handle.net/20.500.12105/20381
dc.description.sponsorshipThis study was supported by the Cooperative Research Thematic Network grant RD12/0036/0061 of the Red de Cancer (Cancer Network of Excellence RTICC); the Subdireccion General de Investigacion Sanitaria (Instituto de Salud Carlos III, Spain) grants PI15/02062 and PI15/01484; the CRIS against Cancer foundation grant 2014/0120; Joan Rodes grant (JR 14/00016); and Undergraduate Fellowship IFI14/00008.es_ES
dc.language.isoengen
dc.publisherNature Publishing Group en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshAged *
dc.subject.meshMale *
dc.subject.meshMonitoring, Physiologic *
dc.subject.meshMultiple Myeloma *
dc.subject.meshNeoplasm, Residual *
dc.subject.meshFemale *
dc.subject.meshHigh-Throughput Nucleotide Sequencing *
dc.subject.meshHumans *
dc.subject.meshSurvival Analysis *
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols *
dc.titleAnalytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myelomaen
dc.typeletter to the editoren
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.identifier.pubmedID28210002es_ES
dc.format.volume31es_ES
dc.format.number6es_ES
dc.format.page1446-1449es_ES
dc.identifier.doi10.1038/leu.2017.58
dc.identifier.e-issn1476-5551es_ES
dc.relation.publisherversionhttps://dx.doi.org/10.1038/leu.2017.58en
dc.identifier.journalLeukemiaes_ES
dc.rights.accessRightsopen accessen
dc.subject.decsHumanos*
dc.subject.decsProtocolos de Quimioterapia Combinada Antineoplásica*
dc.subject.decsAnálisis de Supervivencia*
dc.subject.decsAnciano*
dc.subject.decsMonitoreo Fisiológico*
dc.subject.decsMieloma Múltiple*
dc.subject.decsFemenino*
dc.subject.decsSecuenciación de Nucleótidos de Alto Rendimiento*
dc.subject.decsNeoplasia Residual*
dc.subject.decsMasculino*
dc.identifier.scopus2-s2.0-85014659967
dc.identifier.wos402832700025
dc.identifier.puiL614736600


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 International
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International